CytoSorbents appoints Melanie Grossman as VP & Corp Controller; issues inducement options and RSUs

Cytosorbents Corp

Appointment of Melanie Grossman as VP and Corporate Controller, effective April 14, 2025.
Inducement grant includes 25,000 options at $0.99 exercise price, 10-year term, vesting 50% year 1 then 25% annually.
Also granted 35,000 signing RSUs (change-of-control or 4-year cliff) and 35,000 change-of-control RSUs.
Grossman brings 25 years of experience; previously SVP & Group Controller at Staffing 360 and auditor at Ernst & Young.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.